BACKGROUND: Failure to reach 85% of maximal predicted heart rate (MPHR) during exercise may render a myocardial perfusion single photon emission computed tomography (MPS) study nondiagnostic for ischemia detection. Although commonly used to increase heart rate (HR) during dobutamine stress, the administration of atropine for patients failing to achieve 85% of MPHR during exercise performed for MPS is still infrequent. METHODS AND RESULTS: Patients undergoing dual-isotope MPS were considered candidates for the study when, during exercise treadmill testing, they had less than 85% of MPHR and were unable to continue because of fatigue, without an ischemic response. Forty-seven patients (aged 65.3 +/- 12.5 years, 78.7% men) received atropine (0.6-1.2 mg). Maximal HR achieved before and after atropine was 118.0 +/- 14.8 beats/min (76.3% +/- 6.2% of MPHR) and 146.4 +/- 12.6 beats/min (94.4% +/- 8.1% of MPHR), respectively (P < .001). Of patients, 44 (93.6%) reached at least 85% of MPHR after atropine and had diagnostic MPS studies. After atropine, arrhythmias occurred in 14 patients (29.8%) and other minor side effects in 1 (2.1%). CONCLUSIONS: Atropine allows patients initially failing to achieve 85% of MPHR during exercise to increase HR and have a diagnostic MPS study, without major complications. It may provide an alternative to pharmacologic stress for patients with a blunted HR response to exercise.
BACKGROUND: Failure to reach 85% of maximal predicted heart rate (MPHR) during exercise may render a myocardial perfusion single photon emission computed tomography (MPS) study nondiagnostic for ischemia detection. Although commonly used to increase heart rate (HR) during dobutamine stress, the administration of atropine for patients failing to achieve 85% of MPHR during exercise performed for MPS is still infrequent. METHODS AND RESULTS:Patients undergoing dual-isotope MPS were considered candidates for the study when, during exercise treadmill testing, they had less than 85% of MPHR and were unable to continue because of fatigue, without an ischemic response. Forty-seven patients (aged 65.3 +/- 12.5 years, 78.7% men) received atropine (0.6-1.2 mg). Maximal HR achieved before and after atropine was 118.0 +/- 14.8 beats/min (76.3% +/- 6.2% of MPHR) and 146.4 +/- 12.6 beats/min (94.4% +/- 8.1% of MPHR), respectively (P < .001). Of patients, 44 (93.6%) reached at least 85% of MPHR after atropine and had diagnostic MPS studies. After atropine, arrhythmias occurred in 14 patients (29.8%) and other minor side effects in 1 (2.1%). CONCLUSIONS:Atropine allows patients initially failing to achieve 85% of MPHR during exercise to increase HR and have a diagnostic MPS study, without major complications. It may provide an alternative to pharmacologic stress for patients with a blunted HR response to exercise.
Authors: M L Ladenheim; B H Pollock; A Rozanski; D S Berman; H M Staniloff; J S Forrester; G A Diamond Journal: J Am Coll Cardiol Date: 1986-03 Impact factor: 24.094
Authors: M L Geleijnse; A Elhendy; R T van Domburg; J H Cornel; R Rambaldi; A Salustri; A E Reijs; J R Roelandt; P M Fioretti Journal: Circulation Date: 1997-07-01 Impact factor: 29.690
Authors: P R McLaughlin; R P Martin; P Doherty; S Daspit; M Goris; W Haskell; S Lewis; J P Kriss; D C Harrison Journal: Circulation Date: 1977-03 Impact factor: 29.690
Authors: D S Berman; H Kiat; J D Friedman; F P Wang; K van Train; L Matzer; J Maddahi; G Germano Journal: J Am Coll Cardiol Date: 1993-11-01 Impact factor: 24.094
Authors: S Barai; C D Patel; A Malhotra; G P Bandopadhayaya; S Gambhir; R Kumar; H Dhanapathi Journal: Int J Cardiovasc Imaging Date: 2005-08 Impact factor: 2.357
Authors: Sara L Partington; Viswanatha Lanka; Jon Hainer; Ron Blankstein; Hicham Skali; Daniel E Forman; Marcelo F Di Carli; Sharmila Dorbala Journal: J Nucl Cardiol Date: 2012-05-08 Impact factor: 5.952